Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia

被引:141
作者
Arnold, Donald M. [1 ,2 ]
Nazi, Ishac [1 ]
Warkentin, Theodore E. [3 ]
Smith, James W. [1 ]
Toltl, Lisa J. [1 ]
George, James N. [4 ]
Kelton, John G. [1 ]
机构
[1] McMaster Univ, Dept Med, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[2] Canadian Blood Serv, Hamilton, ON, Canada
[3] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA
关键词
HEPARIN-INDUCED THROMBOCYTOPENIA; PLATELET; ANTIBODIES; RITUXIMAB; EPTIFIBATIDE; PATIENT; PURPURA; CELL; MICROPARTICLES; MEGAKARYOCYTE;
D O I
10.1016/j.tmrv.2013.05.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Drug-induced immune thrombocytopenia (DITP) is a challenging clinical problem that is under-recognized, difficult to diagnose and associated with severe bleeding complications. DITP may be caused by classic drug-dependent platelet antibodies (eg, quinine); haptens (eg, penicillin); fiban-dependent antibodies (eg, tirofiban); monoclonal antibodies (eg, abciximab); autoantibody formation (eg, gold); and immune complex formation (eg, heparin). A thorough clinical history is essential in establishing the diagnosis of DITP and should include exposures to prescription medications, herbal preparations and even certain foods and beverages. Clinical and laboratory criteria have been established to determine the likelihood of a drug being the cause of thrombocytopenia, but these criteria can only be applied retrospectively. The most commonly implicated drugs include quinine, quinidine, trimethoprim/sulfamethoxazole and vancomycin. We propose a practical approach to the diagnosis of the patient with suspected DITP. Key features are: the presence of severe thrombocytopenia (platelet nadir <20 x 10(9)/L); bleeding complications; onset 5 to 10 days after first drug exposure, or within hours of subsequent exposures or after first exposure to fibans or abciximab; and exposure to drugs that have been previously implicated in DITP reactions. Treatment involves stopping the drug(s), administering platelet transfusions or other therapies if bleeding is present and counselling on future drug avoidance. The diagnosis can be confirmed by a positive drug re-challenge, which is often impractical, or by demonstrating drug-dependent platelet reactive antibodies in vitro. Current test methods, which are mostly flow cytometry-based, must show drug-dependence, immunoglobulin binding, platelet specificity and ideally should be reproducible across laboratories. Improved standardization and accessibility of laboratory testing should be a focus of future research. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:137 / 145
页数:9
相关论文
共 64 条
[1]   Thrombocytopenia in a nutshell [J].
Achterbergh, Roos ;
Vermeer, Henricus J. ;
Curtis, Brian R. ;
Porcelijn, Leendert ;
Aster, Richard H. ;
Deenik, Wendy ;
Daemen-Gubbels, Catharine .
LANCET, 2012, 379 (9817) :776-776
[2]  
Adams J, 1999, CANCER RES, V59, P2615
[3]   A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia [J].
Arnold, D. M. ;
Kukaswadia, S. ;
Nazi, I. ;
Esmail, A. ;
Dewar, L. ;
Smith, J. W. ;
Warkentin, T. E. ;
Kelton, J. G. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (01) :169-176
[4]   Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura [J].
Arnold, Donald M. ;
Dentali, Francesco ;
Crowther, Mark A. ;
Meyer, Ralph M. ;
Cook, Richard J. ;
Sigouin, Christopher ;
Fraser, Graeme A. ;
Lim, Wendy ;
Kelton, John G. .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (01) :25-W5
[5]   Integrin β3 regions controlling binding of murine mAb 7E3:: Implications for the mechanism of integrin αIIbβ3 activation [J].
Artoni, A ;
Li, JH ;
Mitchell, B ;
Ruan, J ;
Takagi, J ;
Springer, TA ;
French, DL ;
Coller, BS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (36) :13114-13120
[6]   Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management [J].
Aster, R. H. ;
Curtis, B. R. ;
McFarland, J. G. ;
Bougie, D. W. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (06) :911-918
[7]   Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors [J].
Aster, RH .
CHEST, 2005, 127 (02) :53S-59S
[8]   A PLATELET AND GRANULOCYTE MEMBRANE DEFECT IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - USEFULNESS FOR DETECTION OF PLATELET ANTIBODIES [J].
ASTER, RH ;
ENRIGHT, SE .
JOURNAL OF CLINICAL INVESTIGATION, 1969, 48 (07) :1199-&
[9]  
ASTER RH, 1964, J LAB CLIN MED, V63, P161
[10]   Current concepts - Drug-induced immune thrombocytopenia [J].
Aster, Richard H. ;
Bougie, Daniel W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (06) :580-587